Vera reports FY 2025 net loss of USD 299.6 million, R&D spend USD 215.3 million up 70.6%

Reuters02-26

Vera reports FY 2025 net loss of USD 299.6 million, R&D spend USD 215.3 million up 70.6%

Vera Therapeutics reported a FY 2025 net loss of USD 299.6 million and a net loss per diluted share of USD 4.66. Net cash used in operating activities was USD 241.1 million in FY 2025. The company ended FY 2025 with USD 714.6 million in cash, cash equivalents, and marketable securities. During the period, Vera said the FDA granted priority review to its Biologics License Application for atacicept in IgA nephropathy, with a PDUFA target action date of July 7, 2026, and the company expects a potential U.S. commercial launch in mid-2026 if approved. Vera also highlighted positive Phase 3 ORIGIN 3 data presented at ASN Kidney Week 2025 and published in the New England Journal of Medicine, and noted combined potential gross proceeds of USD 800.0 million from 2025 equity financing and a debt agreement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vera Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602260730PRIMZONEFULLFEED9661860) on February 26, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2614974049?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-26 20:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614974049","market":"fut","top_or_hot":-1,"title":"Vera reports FY 2025 net loss of USD 299.6 million, R&D spend USD 215.3 million up 70.6%","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Vera reports FY 2025 net loss of USD 299.6 million, R&amp;D spend USD 215.3 million up 70.6%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Vera <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> reported a FY 2025 net loss of USD 299.6 million and a net loss per diluted share of USD 4.66. Net cash used in operating activities was USD 241.1 million in FY 2025. The company ended FY 2025 with USD 714.6 million in cash, cash equivalents, and marketable securities. During the period, Vera said the FDA granted priority review to its Biologics License Application for atacicept in IgA nephropathy, with a PDUFA target action date of July 7, 2026, and the company expects a potential U.S. commercial launch in mid-2026 if approved. Vera also highlighted positive Phase 3 ORIGIN 3 data presented at ASN Kidney Week 2025 and published in the <a href=\"https://laohu8.com/S/NEWEN\">New England</a> Journal of Medicine, and noted combined potential gross proceeds of USD 800.0 million from 2025 equity financing and a debt agreement.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vera Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602260730PRIMZONEFULLFEED9661860) on February 26, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vera reports FY 2025 net loss of USD 299.6 million, R&D spend USD 215.3 million up 70.6%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVera reports FY 2025 net loss of USD 299.6 million, R&D spend USD 215.3 million up 70.6%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-26 20:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Vera reports FY 2025 net loss of USD 299.6 million, R&amp;D spend USD 215.3 million up 70.6%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Vera <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> reported a FY 2025 net loss of USD 299.6 million and a net loss per diluted share of USD 4.66. Net cash used in operating activities was USD 241.1 million in FY 2025. The company ended FY 2025 with USD 714.6 million in cash, cash equivalents, and marketable securities. During the period, Vera said the FDA granted priority review to its Biologics License Application for atacicept in IgA nephropathy, with a PDUFA target action date of July 7, 2026, and the company expects a potential U.S. commercial launch in mid-2026 if approved. Vera also highlighted positive Phase 3 ORIGIN 3 data presented at ASN Kidney Week 2025 and published in the <a href=\"https://laohu8.com/S/NEWEN\">New England</a> Journal of Medicine, and noted combined potential gross proceeds of USD 800.0 million from 2025 equity financing and a debt agreement.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vera Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602260730PRIMZONEFULLFEED9661860) on February 26, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0314104364.USD","symbol_name":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDL8bP42W:1","article_id":"2614974049","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614974049","pubTimestamp":1772109120,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Vera Therapeutics reported a FY 2025 net loss of USD 299.6 million and a net loss per diluted share of USD 4.66. Net cash used in operating activities was USD 241.1 million in FY 2025. The company ended FY 2025 with USD 714.6 million in cash, cash equivalents, and marketable securities. During the period, Vera said the FDA granted priority review to its Biologics License Application for atacicept in IgA nephropathy, with a PDUFA target action date of July 7, 2026, and the company expects a potential U.S. commercial launch in mid-2026 if approved. Vera also highlighted positive Phase 3 ORIGIN 3 data presented at ASN Kidney Week 2025 and published in the New England Journal of Medicine, and noted combined potential gross proceeds of USD 800.0 million from 2025 equity financing and a debt agreement.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4588":"碎股","BK4585":"ETF&股票定投概念","VERA":"Vera Therapeutics, Inc.","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","BK4539":"次新股","NDAQ":"纳斯达克OMX交易所","BK4112":"金融交易所和数据","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4139":"生物科技","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC"},"translate_title":"Vera报告2025财年净亏损2.996亿美元，研发支出2.153亿美元，增长70.6%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VERA":0.9,"NDAQ":0.9},"content_text":"Vera reports FY 2025 net loss of USD 299.6 million, R&D spend USD 215.3 million up 70.6%\n    \n\n        Vera Therapeutics reported a FY 2025 net loss of USD 299.6 million and a net loss per diluted share of USD 4.66. Net cash used in operating activities was USD 241.1 million in FY 2025. The company ended FY 2025 with USD 714.6 million in cash, cash equivalents, and marketable securities. During the period, Vera said the FDA granted priority review to its Biologics License Application for atacicept in IgA nephropathy, with a PDUFA target action date of July 7, 2026, and the company expects a potential U.S. commercial launch in mid-2026 if approved. Vera also highlighted positive Phase 3 ORIGIN 3 data presented at ASN Kidney Week 2025 and published in the New England Journal of Medicine, and noted combined potential gross proceeds of USD 800.0 million from 2025 equity financing and a debt agreement.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vera Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602260730PRIMZONEFULLFEED9661860) on February 26, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2614974049","isCrawlerRequest":true}